InflaRx N.V. (NASDAQ:IFRX) Given Consensus Rating of “Moderate Buy” by Brokerages

InflaRx N.V. (NASDAQ:IFRX) has earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $7.00.

A number of equities research analysts have commented on IFRX shares. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Raymond James Financial upgraded shares of InflaRx from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $7.00 to $9.00 in a report on Wednesday, May 13th. Oppenheimer began coverage on shares of InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 price objective for the company. Cantor Fitzgerald boosted their price objective on shares of InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Finally, HC Wainwright upped their target price on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, May 11th.

InflaRx Trading Down 4.6%

Shares of IFRX stock opened at $2.06 on Friday. The company has a market cap of $148.92 million, a price-to-earnings ratio of -2.90 and a beta of 2.44. The stock has a 50 day simple moving average of $2.15 and a 200-day simple moving average of $1.42. InflaRx has a 12-month low of $0.74 and a 12-month high of $2.95.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. On average, equities analysts forecast that InflaRx will post -0.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

A number of institutional investors and hedge funds have recently modified their holdings of the company. 683 Capital Management LLC boosted its position in InflaRx by 47.3% during the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock worth $3,348,000 after purchasing an additional 1,065,000 shares in the last quarter. DCF Advisers LLC purchased a new position in shares of InflaRx in the fourth quarter valued at $160,000. Boothbay Fund Management LLC raised its stake in shares of InflaRx by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock worth $235,000 after buying an additional 17,056 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of InflaRx during the 2nd quarter worth $262,000. Finally, Suvretta Capital Management LLC boosted its position in shares of InflaRx by 22.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock worth $8,013,000 after buying an additional 1,450,000 shares in the last quarter. Institutional investors and hedge funds own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.